Go to the list of all blogs
Joma Foster's Avatar
published in Blogs
Aug 03, 2026
SpaceX (SPCX) Stock Slides -34% Over 30 Days as Lockup and Earnings Loom

SpaceX (SPCX) Stock Slides -34% Over 30 Days as Lockup and Earnings Loom

Key Takeaways

  • SpaceX (SPCX) shares have declined approximately 34% over the past 30 days, falling from $162.00 on July 2 to around $106.33 as of early August, and are now trading well below the June IPO price of $135.
  • The stock's all-time high of $225.64, reached on June 16, has given way to a sustained sell-off that has erased over $1 trillion in market capitalization from peak levels.
  • Massive short interest — estimated at 29% to 56% of the free float — has amplified downward pressure, with short sellers sitting on billions in paper profits since the IPO.
  • A major lockup expiration on August 6 could free up to 911.5 million insider shares for trading, roughly tripling the current public float and creating a potential supply overhang.
  • The company's first-ever quarterly earnings report as a public company, due August 4, represents a critical catalyst that will test whether SpaceX's high-growth narrative can justify its premium valuation.

SpaceX Company Overview and Market Position

Space Exploration Technologies Corp. — widely known as SpaceX — designs, manufactures, and launches advanced rockets and spacecraft. Founded in 2002 by Elon Musk, the company operates three core business segments: space launch services through its Falcon and Starship rocket families, satellite-based broadband connectivity via its Starlink constellation serving over 10 million subscribers across 164 countries, and an artificial intelligence division built around the xAI acquisition completed in early 2026. SpaceX completed the largest IPO in history on June 12, 2026, raising approximately $75 billion at $135 per share. The company's unique vertical integration — controlling launch, satellite deployment, broadband delivery, and AI infrastructure under one roof — positions it as a dominant force across aerospace, telecommunications, and emerging AI computing markets. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

SpaceX Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, SPCX has fallen from a closing price of $162.00 on July 2 to approximately $106.33 in early August — a decline of roughly 34%. The stock broke decisively below its $135 IPO price in mid-July and has continued sliding, establishing a series of lower lows. For the broader quarter — which essentially covers SpaceX's entire seven-week trading history since its June 12 market debut — the stock has declined approximately 21% from its IPO price and roughly 47% from its post-listing intraday peak of $225.64. The initial euphoria that propelled SPCX to a valuation exceeding $2.6 trillion has been replaced by deepening investor scrutiny of the company's profitability path, capital requirements, and near-term share supply dynamics.

What Drove SPCX Stock Price in the Last 30 Days

Several converging forces fueled the sharp 30-day decline. The Starship Flight 13 launch abort on July 16 — when four Raptor engines failed to ignite seconds before liftoff — rattled confidence in the company's execution timeline, sending shares below the IPO price for the first time. Although a successful relaunch on July 24 achieved key milestones including the first deployment of Starlink V3 satellites and an in-space engine relight, the stock failed to recover. Broader market rotation away from high-valuation, capital-intensive technology names compounded the pressure, as investors reassessed AI infrastructure spending returns following concerns raised across the semiconductor and cloud computing sectors. Short sellers aggressively increased their positions, with bearish bets reportedly reaching 34% to 56% of the tradable float — one of the largest short positions in the market. SpaceX's late-June $25 billion bond offering, while bolstering liquidity, reminded investors of the company's substantial debt load and the cost of its AI ambitions. Additionally, the imminent August 6 lockup expiration — allowing early investors and employees to sell up to 911.5 million restricted shares — created a formidable supply overhang. Finally, the company's Q2 earnings report on August 4 looms as the first public test of whether Starlink's profitability and AI revenue growth can offset massive capital expenditures that reached $10.1 billion in Q1 alone. I reviewed recent signals on this using Tickeron’s AI Daily Buy/Sell Signals to get additional context.

What Drove SPCX Stock Performance Over the Last Quarter

Since going public on June 12, SpaceX's stock has traced a dramatic arc from euphoria to deep correction. The IPO priced at $135 and opened at $150, surging to $225.64 within days as retail and institutional investors clamored for a piece of one of the world's most ambitious technology companies. Index inclusion — SPCX was added to the Nasdaq-100 on July 7 — provided an initial demand boost. However, the extreme post-IPO valuation, which at its peak implied a price-to-sales ratio approaching 140x, proved unsustainable as investors shifted focus from narrative to fundamentals. The company's 2025 net loss of $4.9 billion and Q1 2026 net loss of $4.28 billion underscored the gap between ambition and profitability. Starlink, the company's earnings engine, generated $11.4 billion in 2025 revenue with strong margins, but AI-related operating losses of $2.5 billion in Q1 and capital expenditures of $7.7 billion for the AI segment alone raised legitimate questions about the timeline for consolidated profitability. The quarter also featured the acquisition of Anysphere (maker of the Cursor AI coding assistant) for approximately $60 billion in stock, further fueling dilution concerns. Analyst price targets remain bullish — the consensus 12-month target sits near $236 — but a market now pricing for execution risk rather than blue-sky potential has driven the stock materially lower.

SPCX Stock Forecast Drivers: What Investors Should Watch Next

The August 4 Q2 earnings release is the single most important near-term event for SPCX shareholders. Consensus estimates call for revenue of approximately $6.9 billion and an adjusted loss of $0.23 to $0.26 per share, but investors will focus heavily on segment-level profitability, AI revenue ramp, Starlink subscriber growth and average revenue per user trends, and forward capital expenditure guidance. The August 6 lockup expiration represents a critical supply event — even partial insider selling could exert meaningful pressure on a stock with a limited float. Longer term, Starship's path to full reusability and orbital certification will determine whether SpaceX can deploy its next-generation V3 Starlink satellites at scale and pursue orbital data center ambitions. Macroeconomic factors including interest rate policy, AI sector sentiment, and government space and defense contracting will also shape the investment landscape. With short interest at historically elevated levels, any positive catalyst — stronger-than-expected earnings, upbeat guidance, or a major contract announcement — could trigger a rapid short-covering rally, adding to the stock's already pronounced volatility.

AI Trading Bots for Volatile Names

I often turn to Tickeron’s AI Trading Bots when analyzing high-volatility stocks like this one. The platform’s automated strategies provide real-time performance data, historical metrics, and risk profiles across different holding periods, helping me evaluate approaches that align with current market conditions without needing to sift through everything manually. For names with elevated short interest and upcoming catalysts, these tools offer a structured way to review potential signals alongside traditional research.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: SPCX

Notable companies

The most notable companies in this group are GE Aerospace (NYSE:GE), Boeing Company (NYSE:BA), Lockheed Martin Corp (NYSE:LMT), Northrop Grumman Corp (NYSE:NOC), Virgin Galactic Holdings (NYSE:SPCE).

Industry description

Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.

Market Cap

The average market capitalization across the Aerospace & Defense Industry is 41.99B. The market cap for tickers in the group ranges from 4.49 to 1.76T. SPCX holds the highest valuation in this group at 1.76T. The lowest valued company is BDRPF at 4.49.

High and low price notable news

The average weekly price growth across all stocks in the Aerospace & Defense Industry was 3%. For the same Industry, the average monthly price growth was 7%, and the average quarterly price growth was 6%. VOYG experienced the highest price growth at 28%, while EVTL experienced the biggest fall at -36%.

Volume

The average weekly volume growth across all stocks in the Aerospace & Defense Industry was 12%. For the same stocks of the Industry, the average monthly volume growth was 83% and the average quarterly volume growth was 43%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 67
Price Growth Rating: 52
SMR Rating: 78
Profit Risk Rating: 71
Seasonality Score: -27 (-100 ... +100)
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Industry AerospaceDefense

Profile
Details
Interact to see
Advertisement
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Gogo shares continue to trade near 52-week lows around $4, weighed down by competitive threats from Starlink and slower-than-anticipated AVANCE system upgrades. William Blair downgraded the stock to Market Perform in December 2025, citing leverage concerns and intensifying rivalry in in-flight connectivity.
Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.